Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09WKF
|
|||
| Drug Name |
PMID25656651-Compound-36d
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NOVARTIS AG FURET, Pascal GROTZFELD, Robert Martin JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas MOUSSAOUI, Saliha PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph JAHNKE, Wolfgang
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H10Cl2F2N4O2
|
|||
| Canonical SMILES |
C1=CC(=CC=C1NC(=O)C2=CC(=C(N=C2)Cl)C3=CN=CN=C3)OC(F)(F)Cl
|
|||
| InChI |
1S/C17H10Cl2F2N4O2/c18-15-14(11-6-22-9-23-7-11)5-10(8-24-15)16(26)25-12-1-3-13(4-2-12)27-17(19,20)21/h1-9H,(H,25,26)
|
|||
| InChIKey |
BHFPNMRGSVUFLM-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] | |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target's Patent Info | [1] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.